Compare NRO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRO | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 190.3M |
| IPO Year | 2003 | 2014 |
| Metric | NRO | CRBP |
|---|---|---|
| Price | $2.50 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.03 |
| AVG Volume (30 Days) | 219.1K | ★ 808.1K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $2.49 | $4.22 |
| 52 Week High | $3.23 | $19.99 |
| Indicator | NRO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 21.31 |
| Support Level | N/A | N/A |
| Resistance Level | $3.09 | $9.66 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 6.57 | 9.11 |
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.